Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative mFOLFOX6 + Pembrolizumab in Resectable GEJ/Stomach Cancer
NCT02943603Phase 2Withdrawn
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoints: Pathological Complete Response up to 12 weeks and Number of Adverse Events Related to Toxicity up to 31 months. Planned start Jan 2017; status: withdrawn.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02943603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943603.